| __timestamp | Catalyst Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 34916000 |
| Thursday, January 1, 2015 | 8597010 | 36949000 |
| Friday, January 1, 2016 | 7910260 | 45240000 |
| Sunday, January 1, 2017 | 7304399 | 62416000 |
| Monday, January 1, 2018 | 15875961 | 81289000 |
| Tuesday, January 1, 2019 | 36881187 | 100359000 |
| Wednesday, January 1, 2020 | 44233754 | 105326000 |
| Friday, January 1, 2021 | 49628000 | 122356000 |
| Saturday, January 1, 2022 | 58183000 | 152848000 |
| Sunday, January 1, 2023 | 133710000 | 184259000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Corcept Therapeutics Incorporated and Catalyst Pharmaceuticals, Inc. have shown distinct strategies in optimizing these costs. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, peaking in 2023. Meanwhile, Catalyst Pharmaceuticals exhibited a more conservative growth of approximately 290% in the same period.
Corcept's aggressive spending aligns with its rapid expansion and increased market presence, while Catalyst's steady approach reflects a focus on sustainable growth. Notably, in 2023, Corcept's SG&A expenses were about 38% higher than Catalyst's, highlighting its investment in scaling operations. This comparison underscores the diverse strategies companies employ to balance growth and cost efficiency in the dynamic pharmaceutical landscape.
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Novo Nordisk A/S vs Catalyst Pharmaceuticals, Inc.
GSK plc vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
BeiGene, Ltd. or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?
Genmab A/S and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Ligand Pharmaceuticals Incorporated